Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov ID: NCT07154290

Public ClinicalTrials.gov record NCT07154290. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and marlotamig work(s) * The side effects that ubamatamab and marlotamig might cause * How much ubamatamab and marlotamig is in the blood at different times * If the body makes antibodies to ubamatamab and/or marlotamig, this may cause the ubamatamab to not work as well

Study identification

NCT ID
NCT07154290
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
300 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 17, 2026
Primary completion
Jun 9, 2030
Completion
Jun 9, 2030
Last update posted
Aug 24, 2026

2026 – 2030

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
Cancer Treatment Centers of America, Phoenix Goodyear Arizona 85338 Recruiting
The City of Hope Orange County Lennar Foundation Cancer Center Irvine California 92618 Recruiting
Georgetown University Washington D.C. District of Columbia 20007 Recruiting
Mayo Clinic Jacksonville Jacksonville Florida 32224 Recruiting
Rush University Medical Center Chicago Illinois 60612 Recruiting
University of Illinois Chicago Chicago Illinois 60612 Recruiting
Franciscan Health Munster Indiana 46321 Recruiting
University of Maryland Greenebaum Comprehensive Cancer Center Baltimore Maryland 21201 Recruiting
Mayo Clinic Rochester Minnesota 55905 Recruiting
Washington University School of Medicine St Louis Missouri 63110 Recruiting
University of Tennessee Medical Center Knoxville Tennessee 37920 Recruiting
Sarah Cannon Research Institute Nashville Tennessee 37203 Recruiting
University of Texas Medical Branch Galveston Texas 77555 Recruiting
The University of Texas MD Anderson Cancer Center Houston Texas 77030 Recruiting
Baylor Scott & White Health Temple Texas 76508 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07154290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 24, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07154290 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →